| SC 13D/A | 2024-04-30 | HARROW, INC. | Eton Pharmaceuticals, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2024-02-09 | Opaleye Management Inc. | Eton Pharmaceuticals, Inc. | 2,524,887 | 9.8% | EDGAR |
| SC 13G/A | 2023-01-20 | Opaleye Management Inc. | Eton Pharmaceuticals, Inc. | 2,170,000 | 8.6% | EDGAR |
| SC 13D/A | 2022-01-28 | HARROW HEALTH, INC. | Eton Pharmaceuticals, Inc. | - | - | EDGAR |
| SC 13G/A | 2022-01-24 | Opaleye Management Inc. | Eton Pharmaceuticals, Inc. | 2,385,000 | 9.7% | EDGAR |
| SC 13G/A | 2021-06-17 | Opaleye Management Inc. | Eton Pharmaceuticals, Inc. | 9 | 11.0% | EDGAR |
| SC 13G/A | 2021-02-16 | APPEL PETER A | Eton Pharmaceuticals, Inc. | 1,084,329 | 4.5% | EDGAR |
| SC 13G/A | 2020-04-07 | Opaleye Management Inc. | Eton Pharmaceuticals, Inc. | 9 | 11.0% | EDGAR |
| SC 13G/A | 2020-02-14 | Opaleye Management Inc. | Eton Pharmaceuticals, Inc. | 9 | 11.0% | EDGAR |
| SC 13G/A | 2020-02-04 | BRYNJELSEN SEAN | Eton Pharmaceuticals, Inc. | 1,374,940 | 7.6% | EDGAR |
| SC 13G | 2019-05-24 | Opaleye Management Inc. | Eton Pharmaceuticals, Inc. | 9 | 11.0% | EDGAR |
| SC 13G | 2019-02-11 | BRYNJELSEN SEAN | Eton Pharmaceuticals, Inc. | 1,159,940 | 6.6% | EDGAR |
| SC 13D | 2018-11-23 | Imprimis Pharmaceuticals, Inc. | Eton Pharmaceuticals, Inc. | 3,500,000 | 20.7% | EDGAR |
| SC 13G | 2018-11-21 | APPEL PETER A | Eton Pharmaceuticals, Inc. | 1,249,329 | 7.4% | EDGAR |